<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20111212008384N9</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-04-24</date_registration>
      <primary_sponsor>Mashhad University of Medical Sciences</primary_sponsor>
      <public_title>Investigation of the effect of administration of Metformin before surgery on controlling postoperative hyperglycemia in non-diabetic patients</public_title>
      <acronym></acronym>
      <scientific_title>Investigation of the effect of administration of Metformin before surgery on controlling postoperative hyperglycemia in non-diabetic patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-03-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>176</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/62446</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: Block randomization has been used. In this method, 44 blocks of 4 are selected through the relevant sites. Then 88 letters A and 88 letters B were prepared. Opaque envelopes were also used for concealment. 176 envelopes were prepared and the letters A and B were placed inside the envelopes, respectively. The envelopes were sealed and given to the patient's recipient. Each patient was given an envelope (in order) at the time of referral, which the patient provided to the physician. The letter A represented the metformin group and the letter B represented the placebo group, Blinding description: Employees who admitted patients and recorded data did not know patients who received metformin or placebo and were unaware of how individuals were assigned to the two study groups.</study_design>
      <phase>3</phase>
      <hc_freetext>blood suger.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: It consisted of 88 patients receiving one metformin tablet (Merck Sante company, France) at a dose of 500 mg half an hour before surgery orally at a time. Blood glucose, creatinine, and BUN were measured before surgery in these patients. Also, immediately after the operation, the creatinine level, BUN, was measured and blood glucose levels were measured at 6-hour intervals and up to 24 hours after the operation. Intervention 2: Control group: It consisted of 88 patients who received one placebo tablet orally half an hour before surgery at a time. Blood glucose, creatinine, and BUN were measured before surgery in these patients. Also, immediately after the operation, the creatinine level, BUN, was measured and blood glucose levels were measured at 6-hour intervals and up to 24 hours after the operation (Faculty of Pharmacy, Mashhad University of Medical Sciences provided us with a similar pill to metformin without any special drug effect as a placebo).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Data can potentially be shared after people are not identified

When:
The access period starts 6 months after the results are published

To whom:
It will be available to researchers working in academic and scientific institutions

Conditions:
After correspondence with the scientific person in charge of the project and after the publication of the article, by preserving the intellectual rights of the authors, it is possible to access the data and perform analysis on the information.

Where to obtain:
To request data, you can correspond by email to the person in charge of the scientific plan

How to obtain:
To request data, you can correspond by email to the person in charge of the scientific plan

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Arash Peivandi Yazdi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Department of anesthesiology, Imam Reza hospital</address>
        <city>مشهد</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>٩١٣٧٩١٣٣١۶</zip>
        <telephone>+98 51 1802 2677</telephone>
        <email>PeivandiA@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Arash Peivandi Yazdi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Department of anesthesiology, Imam Reza hospital</address>
        <city>مشهد</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>٩١٣٧٩١٣٣١۶</zip>
        <telephone>+98 51 3854 3031</telephone>
        <email>PeivandiA@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Non diabetic patients
ASA class I or II
Candidate for orthopedic surgery in Imam Reza Hospital of Mashhad during 1399 solar year
Ages 18 to 80 years</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>80 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Prohibitions of metformin use, such as acute or chronic renal failure or injury, or a candidate for diagnostic procedures requiring the administration of a contrast agent before and 5 hours after surgery
Dissatisfaction
Allergy to metformin
Patients with ASA above grade II
Drug addicts
Uncomplicated surgical complication
Forcing to use hemodynamic support drugs at any stage of the study
Use non-general anesthesia to perform the procedure
Need re-surgical intervention in the first 24 hours
Diabetic people</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: It consisted of 88 patients receiving one metformin tablet (Merck Sante company, France) at a dose of 500 mg half an hour before surgery orally at a time. Blood glucose, creatinine, and BUN were measured before surgery in these patients. Also, immediately after the operation, the creatinine level, BUN, was measured and blood glucose levels were measured at 6-hour intervals and up to 24 hours after the operation.</i_keyword>
      <i_keyword>Control group: It consisted of 88 patients who received one placebo tablet orally half an hour before surgery at a time. Blood glucose, creatinine, and BUN were measured before surgery in these patients. Also, immediately after the operation, the creatinine level, BUN, was measured and blood glucose levels were measured at 6-hour intervals and up to 24 hours after the operation (Faculty of Pharmacy, Mashhad University of Medical Sciences provided us with a similar pill to metformin without any special drug effect as a placebo).</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Blood suger. Timepoint: after surgery then every 6 hours for 24 hours. Method of measurement: Bs glocometr.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mashhad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-05-19</approval_date>
        <contact_name>Ethics committee of mashhad University of Medical Sciences</contact_name>
        <contact_address>Department of anesthesiology, Imam Reza hospital, Shariati Square mashhad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
